Enterprise Europe Network

Proinflammatory cytokines as a diagnostic marker in the episodic vestibular syndrome

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20190404006
Published
24/04/2019
Last update
02/05/2019
Expiration date
02/05/2020

Keywords

Partner keyword: 
Diagnostics, Diagnosis
Neurology, Brain Research
Diagnostic services
EXPRESS YOUR INTEREST

Summary

Summary: 
A Spanish research group of the public health system has developed a diagnostic technology in the episodic vestibular syndrome (EVS) by using proinflammatory cytokines. A license agreement or an agreement for a public or private partnership for the further development of the patented technology is sought.

Description

Description: 

The episodic vestibular syndrome (EVS) is a clinical condition characterized by recurrent dizziness or vertigo that develops acutely (over seconds, minutes, or hours), may be accompanied by nausea, gait instability, nystagmus, or head-motion intolerance. It disappears clinically within 24 hours and is not linked to head motion, head position/posture or body position/posture.

The classification of the episodic vestibular syndrome (EVS) has always been based on clinical symptoms, and no biological markers have been used for its diagnosis.

The Spanish research group has developed a method of diagnostic using proinflammatory cytokines in the episodic vestibular syndrome. The method is orientated to the patient classification that have Episodic Vestibular Syndrome with migraine and/or with hearing-impaired, with specific approaches for the differential diagnostic of Vestibular Migraine (VM) and Meniere's disease (MD).

Vestibular Migraine (VM) or migrainous vertigo is a type of migraine that may or may not cause a headache, but can include a number of debilitating symptoms affecting the ears, vision and balance.
Meniere's disease (MD) is a disorder of the inner ear that can lead to dizzy spells (vertigo) and hearing loss.

The group is looking for the following collaboration:
-License agreement, in the framework of authorizing the interested parties to use the technology.
-Technical cooperation agreement, to collaborate with other research teams, companies or foundations to improve the technologies.

Advantages & innovations

Cooperation plus value: 
- Biological markers for the diagnostic of Episodic Vestibular Syndrome that differ from the traditional method based on clinical trials. - Differential diagnostic between VM and EM in preliminary stage, allow the pertinent use of therapies, avoiding aggressive treatment in misdiagnosis patients.

Stage of development

Cooperation stage dev stage: 
Available for demonstration

Partner sought

Cooperation area: 
The research group aims to formalize a technology transfer process with entities interested in the implementation of the solution, through a license agreement. If there are some entities, such as R&D centres, technology centres or specialized companies, interested in collaborating and developing further aspects of the solution, a technical cooperation agreement could be envisaged.

Type and size

Cooperation task: 
SME 11-50,University,R&D Institution,SME <10,>500 MNE,251-500,SME 51-250,>500